Skip to content
Retatrutide Order
Which paper studied the change you care about?

Which retatrutide papers can you read for yourself?

A falling weight raises questions about benefits and harms. These papers cover early testing and Phase 2, larger-group testing. They include type 2 diabetes and work from 2024-2026. DOI opens a publisher's paper; PMID and PMC identify research links.

See what happened in people

Where can you read the early Phase 1 study?

You can start with the study's research listing below.

[4] Urva S and colleagues tested LY3437943, now called retatrutide, in type 2 diabetes. The drug copies GLP-1 and two other hormones. Lancet, 2022;400:1869-1881. The study checked how patients responded to early testing. Publisher's paper, doi:10.1016/S0140-6736(22)02033-502033-5). Research listing, PMID:36354040

Where are the weight, diabetes and liver Phase 2 papers?

[1] Jastreboff AM and colleagues. Phase 2 measured weight loss in adults with obesity. new england journal of medicine 2023;389(6):514-526. Paper link, doi:10.1056/NEJMoa2301972. Research listing, PMID:37366315

[2] Rosenstock J and colleagues. Phase 2 compared sugar and weight in type 2 diabetes. Retatrutide copies GIP, GLP-1 and glucagon. Lancet. 2023;402(10401):529-544. Paper link, doi:10.1016/S0140-6736(23)01053-X01053-X). Research listing, PMID:37385280

[5] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. People with excess liver fat had less fat after retatrutide. Nature Medicine. 2024;30:2037-2048. Paper link, doi:10.1038/s41591-024-03018-2. Full paper, PMID:38858523

Where is the lab paper about hormone attachment?

[3] Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. This paper examined drug attachment in a lab. GLP-1R, GIPR and GCGR name proteins where hormones attach. You aren't reading results from patients. Cell Discovery. 2024;10:77. Paper link, doi:10.1038/s41421-024-00700-0. Full paper, PMID:39019866

Which papers reviewed earlier work or offered an opinion?

[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. The authors reviewed weight-loss findings, without testing new patients. Biomolecules. 2025;15:796. Paper link, doi:10.3390/biom15060796. Full paper, PMID:40563436

[7] This review isn't an approval notice for the drug. Clinical Diabetes 2024. Paper link, doi:10.2337/cd24-0062. Research listing, PMID:39724554. Full-paper copy, PMC: PMC11486854

[8] The review compared seven hormone-based drugs. Separate studies can't choose your medicine. Review 2024. Research listing, PMID:39305981

[9] Deravi M and colleagues. The authors discussed earlier results, without another patient test. journal of pharmacy technology 2024;40(6):300-305. Paper link, doi:10.1177/87551225241285326. Research listing, PMID:39507873. Full-paper copy, PMC: PMC11536522

[10] Kusminski CM and colleagues. This review compared hormone-based weight loss with surgery. Similar losses don't assure your safety. Cell. 2024;187(15):3829-3853. Paper link, doi:10.1016/j.cell.2024.06.003. Research listing, PMID:39059360. Full-paper copy, PMC: PMC11286204

[11] Naeem M and colleagues. This letter expressed hope, without a new trial. health science reports 2024;7(2):e1864. Paper link, doi:10.1002/hsr2.1864. Research listing, PMID:38323122. Full-paper copy, PMC: PMC10844714

What did the 2024-2026 papers add?

[12] This review examined GLP-1 and cravings. Retatrutide mood benefits aren't proved. Medical Sciences (Basel) 2025;13(3):136. Paper link, doi:10.3390/medsci13030136. Full-paper copy, PMC: PMC12372146. Read the full paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/

[13] Pearson MJ and colleagues. Researchers checked blood fats in people with excess weight. Some had type 2 diabetes; others did not. Journal of Clinical Endocrinology & Metabolism 2026. Paper link, doi:10.1210/clinem/dgag201. Research listing, PMID:42135195

[14] Wen Y and colleagues. Blood fats fell alongside ANGPTL3/8, proteins affecting fat removal from blood. That protein name identifies what researchers measured. These blood tests don't establish lasting heart protection for you. Diabetes, Obesity & Metabolism 2025. Paper link, doi:10.1111/dom.16661. Research listing, PMID:40726454

[15] Lu X and colleagues. This review discussed reasons for liver changes, without a new patient trial. Frontiers in Medicine 2026. Paper link, doi:10.3389/fmed.2026.1763185. Research listing, PMID:41767516

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗
  8. et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss. [review] 2024. ↗
  9. Deravi M, et al. The 'Weight' for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. J Pharm Technol. 2024;40(6):300-305. ↗
  10. Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. ↗
  11. Naeem M, et al. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024;7(2):e1864. ↗
  12. et al. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological Insights. Med Sci (Basel). 2025;13(3):136. ↗
  13. Pearson MJ, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. ↗
  14. Wen Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025. ↗
  15. Lu X, et al. Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research. Front Med. 2026. ↗